Kintor Pharmaceutical Limited (HKEX: 9939), a China-based clinical-stage biotechnology company, announced on Tuesday that it has completed the enrolment of 740 subjects in the phase three clinical trial of its in-house developed first-in-class drug candidate KX-826 (pyrilutamide) in China to treat male androgenetic alopecia (AGA) in adults.

The Phase III clinical trial, a randomised, double-blind, placebo-controlled, multi-regional study, is aimed at assessing the efficacy and safety of 5mg (0.5% concentration) of KX-826 twice daily (BID) for treating male AGA adults in China.

The leading principal investigators (leading PIs) of this trial are Professor Zhang Jianzhong from Peking University People's Hospital and Professor Yang Qinping from Huashan Hospital Affiliated to Fudan University.

The clinical trial's primary endpoint is the change from baseline in non-vellus target area hair counts (TAHC) after 24 weeks of treatment in comparison to placebo. The safety endpoints primarily include the type, incidence and severity of adverse events.